QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 canaccord-genuity-maintains-buy-on-atricure-raises-price-target-to-64

Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $53 ...

 atricure-raises-fy2025-adj-eps-guidance-from-039-034-to-026-023-vs-049-est-raises-fy2025-sales-guidance-from-527000m-533000m-to-532000m-534000m-vs-530651m-est

AtriCure (NASDAQ:ATRC) raises FY2025 Adj EPS guidance from $(0.39)-$(0.34) to $(0.26)-$(0.23) vs $(0.49) analyst estimate. Rais...

 atricure-q3-adj-eps-001-beats-012-estimate-sales-134269m-beat-131254m-estimate

AtriCure (NASDAQ:ATRC) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.12) by 9...

 atricure-enrolls-treats-first-patient-in-boxx-noaf-clinical-study-in-orlando-florida

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left at...

 needham-maintains-buy-on-atricure-raises-price-target-to-45

Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $44 to $45.

 atricure-raises-fy2025-adj-eps-guidance-from-055-050-to-039-034-vs-053-est-raises-fy2025-sales-guidance-from-517000m-527000m-to-527000m-533000m-vs-522898m-est

AtriCure (NASDAQ:ATRC) raises FY2025 Adj EPS guidance from $(0.55)-$(0.50) to $(0.39)-$(0.34) vs $(0.53) analyst estimate. Rais...

 atricure-q2-adj-eps-002-beats-017-estimate-sales-136139m-beat-130171m-estimate

AtriCure (NASDAQ:ATRC) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.17) by 8...

 atricure-completes-enrollment-in-left-atrial-appendage-exclusion-for-prophylactic-stroke-reduction-clinical-trial

Largest cardiac surgery device trial ever with 6,500 patients enrolled, this landmark trial evaluates the stroke reduction bene...

 ubs-maintains-buy-on-atricure-lowers-price-target-to-58

UBS analyst Danielle Antalffy maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $60 to $58.

 jmp-securities-reiterates-market-outperform-on-atricure-maintains-60-price-target

JMP Securities analyst Daniel Stauder reiterates AtriCure (NASDAQ:ATRC) with a Market Outperform and maintains $60 price tar...

 needham-maintains-buy-on-atricure-lowers-price-target-to-44

Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $51 to $44.

 atricure-raises-fy2025-adj-eps-guidance-from-064-057-to-055-050-vs-066-est-affirms-fy2025-sales-guidance-of-51700m-52700m-vs-52279m-est

AtriCure (NASDAQ:ATRC) raises FY2025 Adj EPS guidance from $(0.64)-$(0.57) to $(0.55)-$(0.50) vs $(0.66) analyst estimate. Affi...

 atricure-q1-adj-eps-014-beats-023-estimate-sales-12362m-beat-12292m-estimate

AtriCure (NASDAQ:ATRC) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.23) by 3...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION